Q2 EPS Forecast for Puma Biotechnology Reduced by Analyst

Puma Biotechnology, Inc. (NASDAQ:PBYIFree Report) – Analysts at Zacks Research dropped their Q2 2025 earnings estimates for Puma Biotechnology in a report issued on Wednesday, April 30th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings of $0.08 per share for the quarter, down from their previous forecast of $0.09. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology’s FY2025 earnings at $0.48 EPS, Q3 2026 earnings at $0.13 EPS and Q4 2026 earnings at $0.02 EPS.

Other equities research analysts have also recently issued research reports about the company. StockNews.com raised Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 25th. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Puma Biotechnology in a research report on Friday, February 28th.

Read Our Latest Stock Report on PBYI

Puma Biotechnology Trading Up 4.2 %

NASDAQ:PBYI opened at $3.21 on Friday. Puma Biotechnology has a 12 month low of $2.23 and a 12 month high of $5.26. The company has a current ratio of 1.42, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $159.32 million, a price-to-earnings ratio of 6.69 and a beta of 1.29. The firm has a fifty day simple moving average of $3.13 and a two-hundred day simple moving average of $3.03.

Puma Biotechnology (NASDAQ:PBYIGet Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $0.29. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. The company had revenue of $59.10 million for the quarter, compared to the consensus estimate of $52.50 million.

Institutional Trading of Puma Biotechnology

Several institutional investors and hedge funds have recently made changes to their positions in PBYI. Tower Research Capital LLC TRC grew its position in Puma Biotechnology by 167.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,137 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 6,351 shares in the last quarter. Gateway Wealth Partners LLC bought a new position in shares of Puma Biotechnology in the fourth quarter valued at approximately $31,000. Graham Capital Management L.P. purchased a new stake in shares of Puma Biotechnology during the fourth quarter valued at approximately $33,000. ProShare Advisors LLC bought a new stake in Puma Biotechnology during the fourth quarter worth $36,000. Finally, C2C Wealth Management LLC purchased a new position in Puma Biotechnology in the fourth quarter worth $37,000. Hedge funds and other institutional investors own 61.29% of the company’s stock.

Puma Biotechnology Company Profile

(Get Free Report)

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.

See Also

Earnings History and Estimates for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.